[go: up one dir, main page]

BR9915027A - Derivados de 1,3-diaril-2-piridin-2-il-3-(3-piridin-2-ilamino)-propanol susbtituìdos, processos para a sua preparação, medicamentos contendo estes compostos e seu emprego - Google Patents

Derivados de 1,3-diaril-2-piridin-2-il-3-(3-piridin-2-ilamino)-propanol susbtituìdos, processos para a sua preparação, medicamentos contendo estes compostos e seu emprego

Info

Publication number
BR9915027A
BR9915027A BR9915027-1A BR9915027A BR9915027A BR 9915027 A BR9915027 A BR 9915027A BR 9915027 A BR9915027 A BR 9915027A BR 9915027 A BR9915027 A BR 9915027A
Authority
BR
Brazil
Prior art keywords
pyridin
derivatives
diaryl
propanol
ylamino
Prior art date
Application number
BR9915027-1A
Other languages
English (en)
Other versions
BR9915027B1 (pt
Inventor
Reinhard Kirsch
Alfons Enhsen
Heiner Glombik
Werner Kramer
Eugen Falk
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of BR9915027A publication Critical patent/BR9915027A/pt
Publication of BR9915027B1 publication Critical patent/BR9915027B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Patente de Invenção: <B>"DERIVADOS DE 1,3-DIARIL-2-PIRIDIN-2-IL-3-(3-PIRIDIN-2-ILAMINO)-PROPANOL SUBSTITUìDOS, PROCESSOS PARA A SUA PREPARAçãO, MEDICAMENTOS CONTENDO ESTES COMPOSTOS E SEU EMPREGO"<D>. A invenção refere-se a derivados de 1,3-diaril-2-piridin-2-il-3-(piridin-2-ilamino)-propanol substituídos e seus sais farmaceuticamente compatíveis e derivados fisiologicamente funcionais. São descritos derivados de 1,3-diaril-2-piridin-2-il-3-(piridin-2-ilamino)-propanol substituídos da fórmula I copiar fórmula página 79, na qual os radicais têm os significados indicados, bem como seus sais fisiologicamente compatíveis e processos para sua preparação. Os compostos prestam-se, por exemplo, como hipolipidêmicos.
BRPI9915027-1A 1998-10-02 1999-09-18 derivados de 1,3-diaril-2-piridin-2-il-3-(3-piridin-2-ilamino)-propanol susbtituìdos, medicamento contendo tais compostos, processo de preparação do mesmo, e aplicação dos mesmos. BR9915027B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19845406A DE19845406C2 (de) 1998-10-02 1998-10-02 Substituierte 1,3-Diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)- propanolderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
PCT/EP1999/006933 WO2000020393A1 (de) 1998-10-02 1999-09-18 Substituierte 1,3-diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)-propanolderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung

Publications (2)

Publication Number Publication Date
BR9915027A true BR9915027A (pt) 2001-07-17
BR9915027B1 BR9915027B1 (pt) 2010-09-08

Family

ID=7883187

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9915027-1A BR9915027B1 (pt) 1998-10-02 1999-09-18 derivados de 1,3-diaril-2-piridin-2-il-3-(3-piridin-2-ilamino)-propanol susbtituìdos, medicamento contendo tais compostos, processo de preparação do mesmo, e aplicação dos mesmos.

Country Status (22)

Country Link
US (1) US6596728B1 (pt)
EP (1) EP1117642B1 (pt)
JP (1) JP4544746B2 (pt)
KR (1) KR100609255B1 (pt)
CN (1) CN1173951C (pt)
AR (1) AR021845A1 (pt)
AT (1) ATE267809T1 (pt)
AU (1) AU757689B2 (pt)
BR (1) BR9915027B1 (pt)
CA (1) CA2345985C (pt)
CZ (1) CZ299569B6 (pt)
DE (2) DE19845406C2 (pt)
DK (1) DK1117642T3 (pt)
ES (1) ES2219066T3 (pt)
HU (1) HU226688B1 (pt)
ID (1) ID29249A (pt)
PL (1) PL205034B1 (pt)
PT (1) PT1117642E (pt)
RU (1) RU2224748C2 (pt)
TR (1) TR200100896T2 (pt)
WO (1) WO2000020393A1 (pt)
ZA (1) ZA200102587B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL156548A0 (en) 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
DE10064402A1 (de) * 2000-12-21 2002-06-27 Aventis Pharma Gmbh Diphenylazetidinonderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
HRP20040172A2 (en) * 2001-08-22 2004-10-31 Aventis Pharma Gmbh Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof
DE10219987A1 (de) * 2002-05-03 2004-04-08 Aventis Pharma Deutschland Gmbh Optisch aktive β-Aminoketone, optisch aktive 1,3-Aminoalkohole und Verfahren zu deren Herstellung
US7161008B2 (en) * 2002-05-03 2007-01-09 Sanofi - Aventis Deutschland GmbH Optically active β-aminoketones, optically active 1,3-amino alcohols and processes for preparing them
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
JP4800216B2 (ja) * 2003-10-24 2011-10-26 エグゼリクシス， インコーポレイテッド ｐ７０Ｓ６キナーゼモジュレーターおよび使用方法
EP4137137A1 (en) 2010-05-26 2023-02-22 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
EP2770990A4 (en) 2011-10-28 2015-03-11 Lumena Pharmaceuticals Inc Gallic acid refluxing agent for the treatment of hypertension and chronic liver disease
PT2771003T (pt) 2011-10-28 2017-07-26 Lumena Pharmaceuticals Llc Inibidores da reciclagem de ácidos biliares para tratamento de doenças hepáticas colestáticas pediátricas
AU2014228850A1 (en) 2013-03-15 2015-10-29 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
MX2015013196A (es) 2013-03-15 2016-04-15 Lumena Pharmaceuticals Inc Inhibidores de reciclaje de acidos biliares para el tratamiento de la enfermedad de reflujo gastroesofagico y esofago de barrett.
JP6361168B2 (ja) * 2013-06-17 2018-07-25 Jsr株式会社 液晶配向剤、液晶配向膜、液晶表示素子、液晶表示素子の製造方法、重合体及び化合物
WO2020167964A1 (en) 2019-02-12 2020-08-20 Mirum Pharmaceuticals, Inc. Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0000816A1 (en) * 1977-08-06 1979-02-21 Beecham Group Plc Substituted amino-pyridine derivatives, processes for their preparation and pharmaceutical compositions containing them
SU1194273A3 (ru) * 1981-02-09 1985-11-23 Пфайзер Инк (Фирма) Способ получени пирбутерола или его аналогов
GB9203347D0 (en) * 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
EP0557879B1 (de) * 1992-02-22 1997-01-08 Hoechst Aktiengesellschaft 4-Amino-2-ureido-pyrimidin-5-carbonsäureamide, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE19845402B4 (de) * 1998-10-02 2005-04-07 Aventis Pharma Deutschland Gmbh Mit Heterocyclen substituierte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
ES2223091T3 (es) 1997-04-04 2005-02-16 Aventis Pharma Deutschland Gmbh Derivados de propanolamina hipolipidemicos.
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung

Also Published As

Publication number Publication date
CA2345985C (en) 2010-06-29
KR20010075496A (ko) 2001-08-09
HK1051533A1 (en) 2003-08-08
ZA200102587B (en) 2001-11-05
CZ20011152A3 (cs) 2001-07-11
JP4544746B2 (ja) 2010-09-15
ES2219066T3 (es) 2004-11-16
DE59909606D1 (de) 2004-07-01
TR200100896T2 (tr) 2001-09-21
ID29249A (id) 2001-08-16
HU226688B1 (hu) 2009-06-29
DK1117642T3 (da) 2004-08-09
PL205034B1 (pl) 2010-03-31
PL347096A1 (en) 2002-03-25
CA2345985A1 (en) 2000-04-13
DE19845406A1 (de) 2000-04-13
EP1117642B1 (de) 2004-05-26
DE19845406C2 (de) 2001-10-18
BR9915027B1 (pt) 2010-09-08
RU2224748C2 (ru) 2004-02-27
WO2000020393A1 (de) 2000-04-13
AU6192699A (en) 2000-04-26
HUP0103533A2 (hu) 2002-02-28
ATE267809T1 (de) 2004-06-15
AU757689B2 (en) 2003-03-06
CZ299569B6 (cs) 2008-09-03
EP1117642A1 (de) 2001-07-25
AR021845A1 (es) 2002-08-07
KR100609255B1 (ko) 2006-08-04
HUP0103533A3 (en) 2003-01-28
CN1173951C (zh) 2004-11-03
US6596728B1 (en) 2003-07-22
PT1117642E (pt) 2004-09-30
CN1391558A (zh) 2003-01-15
JP2002526530A (ja) 2002-08-20

Similar Documents

Publication Publication Date Title
BR9915967A (pt) Derivados de propanolamina substituìdos por arila, proceso para sua preparação, medicamentos contendo estes compostos e seu uso
BR9914266A (pt) Derivados de propanolamina substituìdos por heterociclos, processos para a sua preparação, medicamentos contendo estes compostos e seu emprego
BR0111457A (pt) Derivados de acilfeniluréia, processos para a sua preparação e sua aplicação como medicamentos
BRPI0510770A (pt) derivados de fluorglicosìdeos de pirazóis, medicamentos contendo esses compostos e seu uso
BR0316605A (pt) Derivados de fluorglicosìdeos aromáticos, medicamentos contendo estes compostos e sua aplicação
BR0317283A (pt) Derivados heterocìclicos de flúor-glicosìdeo, medicamentos contendo estes compostos e seu uso
BR9912188A (pt) Derivados de 1,1-dióxido de benzo (b) tiepina, processos para a sua preparação, medicamentos contendo estes compostos e sua aplicação
BR0116322A (pt) Derivados de difenilazetidinona, processo para sua preparação, medicamentos contendo esses compostos e seu emprego
BR9915027A (pt) Derivados de 1,3-diaril-2-piridin-2-il-3-(3-piridin-2-ilamino)-propanol susbtituìdos, processos para a sua preparação, medicamentos contendo estes compostos e seu emprego
BR0008331A (pt) Derivados de 16-halogeno-epotilon, processos para a sua preparação e seu emprego farmacêutico
BR0215312A (pt) Uso de um composto, método para inibir a aurora quinase em um animal de sangue quente, composto, composição farmacêutica, e, processo para a preparação de um composto
BR0211995A (pt) Preparados de combinação de derivados de propanolamina substituìdos por arila com outras substâncias ativas e sua aplicação
BR0009641A (pt) Derivados de 1,4-benzotiazepin-1,1-dióxido, substituìdos com radicais de açúcar, processo para produção dos mesmos, medicamentos contendo esses compostos e sua utilização
BR0116482A (pt) Derivados de difenilazetidinona, processo para a preparação, medicamentos contendo esses compostos e seu emprego.
BR0015322A (pt) Derivados de indeno-, nafto- e benzociclohepta-dihidrotiazol, sua preparação e seu emprego como medicamentos anoréticos
BR9814416A (pt) &#34;estratrienos substituìdos por 11beta-halogeno-7alfa, processos para a preparação de preparados farmacêuticos, que contêm estes estratrienos substituìdos por 11-beta-7alfa, bem como seu emprego para a preparação de medicamentos&#34;
BRPI0112986B8 (pt) compostos azabicíclicos, processo para a sua preparação, bem como composições farmacêuticas compreendendo os ditos compostos
BR0312513A (pt) Derivados de glicosìdeo de tiofeno, processos para a produção dos mesmos, medicamentos que contêm esses compostos e uso dos mesmos
BR0108605A (pt) Derivados de 8,8a-dihidro-indeno[1,2-d]tiazol, que na posição 8a são substituìdos; processos para a sua preparação e seu emprego como medicamentos, por exemplo, como anoréxicos
BRPI0407387A (pt) Derivados de hexahidro-pirazino[1,2-a]pirimidin-4,7-diona substituìdos por nitrogênio, processos para a sua preparação e sua aplicação com medicamento
BRPI0407734A (pt) derivados de adamantano, processo para sua preparação e composições farmacêuticas os contendo
BR0312697A (pt) Benzoiluréias substituìdas heterociclicamente, processo para a sua preparação e sua aplicação como medicamento
BRPI9917007B8 (pt) azabicicloalcanos como moduladores de ccr5, composição farmacêutica contendo os mesmos, bem como seu uso
BR9912240A (pt) Benzocicloheptenos, processo para a sua preparação, preparados farmacêuticos, que contêm os mesmos bem como seu emprego para a preparação de medicamentos
BRPI0407507A (pt) derivados de hexahidro-pirazino[1,2-a]pirimidin-4,7-diona, processos para sua preparação de sua aplicação como medicamento

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH

B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: REFERENTE A RPI 1865 DE 03/10/2006 COD. (25.1), POR TER SIDO INDEVIDO.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: C07D 401/12, C07D 401/14, C07D 409/14, C07D 405/14, C07D 417/14, C07D 471/01, C07D 473/08, C07D 473/34, C07D 413/14, A61K 31/44, A61K 31/513, A61K 31/437, A61K 31/52, A61K 31/522, A61P 3/06, A61P 9/10

Ipc: C07D 401/12 (2009.01), C07D 401/14 (2009.01), C07D

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/09/2010, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.